INTRODUCTION {#s1}
============

Gastric cancer is the second leading cause of cancer-related death worldwide, and the 5-year survival is 28% in 2014 \[[@R1]\]. Although the incidence of gastric cancer has declined in the past several years, it remains the most common cancer in many geographic regions, including Eastern Asia, Eastern Europe and Southern/Central American \[[@R2]\].

Currently, the widely used AJCC 7th TNM staging system is the most common tool to predict survival for gastric cancer. It stratifies RGC patients into seven groups \[[@R3]\]. Additionally, our previous study showed the ratio between metastatic and examined lymph nodes (mLNR) based staging system (TRM) is superior to the AJCC 7th system. The new classification can reduce stage migration and provide more reliable prognostic information \[[@R4]--[@R6]\].

Recently, nomograms have been established in many types of cancers \[[@R7]--[@R12]\]. It is a simple tool to predict individualized survival by incorporating more risk factors such as sex, age and size of the tumor \[[@R13]\]. However, besides tumor-related factors, the survival of cancer patients is also dependent on host\'s reaction to the tumor. Especially the host inflammatory response markers (SIRMs), a powerful prognostic factors, has not ever been included as a risk group in previous nomograms \[[@R14]--[@R24]\].

In this study, we established a nomogram combined clinicopathology characteristics and routine detected SIRMs, to determine whether this model predict a more accurate survival for RGC patients following D2 resection when compared with the currently TNM staging system.

RESULTS {#s2}
=======

Clinical characteristics of patients {#s2_1}
------------------------------------

A retrospective study was conducted on a primary cohort, who underwent D2 resection between January 1, 2005 and December 31, 2010 at the Sun Yat-sen University Cancer Center. Of 3,452 RGC patients, 1058 patients met all the inclusion and exclusion criteria. The patients operated between January 1, 2005 and December 31, 2009 were assigned to the training set (817 patients) for the construction of a nomogram, and the rest (241 patients) between January 1, 2010 and December 31, 2010 were selected as validation set. The characteristics of those patients are listed in Table [1](#T1){ref-type="table"}. The median follow-up is 39.4 months in training set and 28.6 months in validation set.

###### Characteristic of training set and validation set

                              Training set(n=817)   Validation set(n=241)   p              
  --------------------------- --------------------- ----------------------- ------- ------ -------
  Age (years)                                                                              0.450
    Median                    57.7±11.9             58.7±11.4                              
    Range                     19 to 89              21 to 81                               
  Sex                                                                                      0.295
    Male                      547                   67.0                    170     70.5   
    Female                    270                   33.0                    71      29.5   
  Tumor size (cm)                                                                          0.170
    Mean±SD                   4.6±2.7               4.3±2.4                                
    Range                     0.2 to 21.0           0.8 to 14.0                            
  Tumor location                                                                           0.555
    Upper                     342                   41.9                    93      38.6   
    Middle                    160                   19.6                    46      19.1   
    Lower                     315                   38.6                    102     42.3   
  Pathology type                                                                           0.008
    Differentiated            289                   35.4                    108     44.8   
    Undifferentiated          528                   64.6                    133     55.2   
  Depth of invasion                                                                        0.001
    Mucosa or submucosa       107                   13.1                    35      14.5   
    Proper muscle             82                    10.0                    32      13.3   
    Subserosa                 163                   20.0                    104     43.2   
    Serosa                    363                   44.4                    60      24.9   
    Adjacent invasion         102                   12.5                    10      4.1    
  Positive LN (Mean±SD)       6.2±8.5               5.7±7.7                 0.380          
  Total LN (Mean±SD)          25.0±11.7             24.6±11.1               0.692          
  mLNR (Mean±SD)              0.2±0.3               0.2±0.3                 0.138          
  AJCC 7th Stage                                                                           0.002
    IA                        83                    10.2                    29      12.0   
    IB                        61                    7.5                     22      9.1    
    IIA                       57                    7.0                     32      13.3   
    IIB                       134                   16.4                    36      14.9   
    IIIA                      88                    10.8                    34      14.1   
    IIIB                      167                   20.4                    48      19.9   
    IIIC                      227                   27.8                    40      16.6   
  CEA (ug/ml)                 11.3±52.4             12.5±57.6               0.676          
  Total Protein (g/l)         67.2±6.7              68.9±6.2                0.155          
  Albumin (g/l)               41.2±4.3              41.5±3.9                0.226          
  Globin (g/l)                26.0±4.4              27.3±4.2                0.448          
  C-reactive protein (mg/l)   8.2±19.9              9.3±31.0                0.337          
  CAR(mg/g)                                         0.245                                  
    ≤0.05                     418                   51.2                    124     51.5   
    0.05-0.18                 212                   25.9                    75      31.1   
    ≥0.18                     187                   22.9                    42      17.4   
  WBC (×10^9^/l)              6.6±1.8               6.5±1.6                 0.066          
  Hemoglobin (g/l)            123.0±24.4            129.1±24.3              0.105          
  Neutrophil (×10^9^/l)       4.0±1.5               4.1±1.4                 0.083          
  Lymphocyte (×10^9^/l)       1.9±0.6               1.8±0.6                 0.063          
  Palate (×10^9^/l)           252.9±97.2            244.1±79.5              0.074          
  NLR                                               0.936                                  
    ≤1.30                     136                   16.6                    19      7.9    
    1.30-3.71                 589                   72.1                    190     78.8   
    ≥3.71                     92                    11.3                    32      13.3   

Abbreviation: LN, lymph node; mLNR, metastatic lymph node ratio; AJCC, American joint Committee on Cancer; GB, globin; CAR, C-reactive protein to albumin ratio; NLR, neutrophil to lymphocyte ratio.

Independent risk factors in the training set {#s2_2}
--------------------------------------------

In the current study, the best cutoff points for C-reactive protein to albumin ratio (CAR) were 0.05 and 0.18 ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). And the best cutoff points for Neutrophil to lymphocyte ratio (NLR) were 1.30 and 3.71 ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Univariate analysis showed that the age at diagnosis, location, pathological type, depth of invasion, mLNS, mLNR, AJCC 7th stage, NLR, ALB, CRP, CEA and CAR were associated with OS. Multivariate analysis with Cox PH regression showed that age at diagnosis, location, pathological type, depth of invasion, mLNS/mLNR, NLR and CAR were independent risks for overall survival (Table [2](#T2){ref-type="table"}). Based on the multivariate analysis, six models were constructed: AJCC staging system; Nomogram A based on AJCC staging system and SIRMs; Nomogram B based on mLNS; Nomogram C based on mLNR; Nomogram D based on mLNS and SIRMs; Nomogram E based on mLNR and SIRMs.

###### Multivariate Analysis of the training set

                          Hazard ratio   95% CI          *p*
  ----------------------- -------------- --------------- ---------
  Age                     1.02           1.01 to 1.03    \<0.001
  Location                                               \<0.001
    Lower                 ref                            
    Middle                1.62           1.17 to 2.24    
    Upper                 1.81           1.38 to 2.36    
  Pathological type       0.64           0.50 to 0.81    \<0.001
  Depth of invasion                                      \<0.001
    Mucosa or submucosa   ref                            
    Proper muscle         2.14           0.88 to 5.23    
    Subserosa             2.88           1.28 to 6.42    
    Serosa                3.97           1.83 to 8.64    
    Adjacent invasion     5.11           2.28 to 11.45   
  mLNR                    7.99           5.47 to 11.67   \<0.001
  CAR                                                    \<0.001
    ≤0.05                 ref                            
    0.05-0.18             1.32           1.00 to 1.75    
    ≥0.18                 2.27           1.73 to 2.97    
  NLR                                                    0.019
    ≤1.30                 ref                            
    1.30-3.71             1.41           0.96 to 2.06    
    ≥3.71                 1.91           1.21 to 3.03    

Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to albumin ratio.

Development and validated the nomogram for gastric cancer {#s2_3}
---------------------------------------------------------

The risk factors which were statistically significant in multivariate analysis were incorporated intothe prognostic nomogram (Figure [1](#F1){ref-type="fig"}). When the nomogram including depth of invasion, mLNS, age, location, pathological type and SIRMs, the C-index for predicting OS was 0.77, which were significantly lower than that of the nomogram including depth of invasion, mLNR, age, location, pathological type and SIRMs (0.80; p =0.005). It suggests that the discrimination power of mLNR is better than mLNS in this nomogram. Additionally, according to the total score identified on the points scale, the current nomogram clearly assigned the probability of 1-year, 3-year and 5-year OS.

![Nomogram predicting 1-year, 3-year and 5-year OS for RGC patients after D2 resection\
The nomogram is used by adding up the points identified on the points scale for each variable. According to the sum of these points projected on the bottom scales, the nomogram can provide the likehood of 1-year, 3-year and 5-year OS for an individual patient. Abbreviation: mLNR, metastatic lymph node ratio; NLR, neutrophil to lymphocyte ratio; CAR, C-reactive protein to Albumin ratio; OS, overall survival; RGC, resectable gastric cancer.](oncotarget-07-37556-g001){#F1}

Validation of predictive accuracy for OS of the nomogram {#s2_4}
--------------------------------------------------------

In the validation set, the C-index of the nomogram included mLNR for predicting OS was 0.79 (95% CIs 0.74-0.84; p\<0.001), higher than that of AJCC 7th staging system(C-index=0.70; 95% CIs 0.64-0.76; p\<0.001). Furthermore, as shown in Figure [2](#F2){ref-type="fig"}, the probability of 1-year, 3-year and 5-year survival in this nomogram corresponded closely between prediction and observation. In addition, Figure [3A](#F3){ref-type="fig"} shows the Kaplan-Meier survival curve of the primary cohort categorized by the AJCC 7th staging system, with no good discrimination between stage I and stage II patients. However, by the proposed nomogram, a wider range of predicted survival than AJCC-TNM staging system could be clearly identified within each TNM categories (Figure [3B](#F3){ref-type="fig"}).

![The calibration curve for predicting patients overall survival at 1-year\
**A.** 3-year **B.** and 5-year **C.** in the training set and predicting overall survival at 1-year **D.** and 3-year **E.** in the validation set, 5-year **F.** in the primary cohort. The X-axis represents the nomogram-predicted survival, and the actual survival is plotted on the Y-axis. The dotted line represents the ideal correlationship between predicted and actual survival.](oncotarget-07-37556-g002){#F2}

![**A.** Overall survival by AJCC 7th staging system in primary cohort; **B.** Distribution of nomogram-predicted 5-year overall survival within each AJCC 7th stage grouping.](oncotarget-07-37556-g003){#F3}

Comparison of predictive accuracy for OS in different nomogram models {#s2_5}
---------------------------------------------------------------------

As shown in Figure [4](#F4){ref-type="fig"}, our nomogram displayed optimal outcome-predicting accuracy in the validation set. The C-index of the proposed Nomogram was 0.79, which was higher than the AJCC 7th staging system (0.70), the potential Nomogram A (0.76, P\<0.001), the potential Nomogram B (0.73, P\<0.001), the potential Nomogram C (0.75, P\<0.001) and the potential Nomogram D (0.77, P=0.005). These results indicated that the proposed nomogram was a useful predictor in predicting both short- and long-term survival of patients with RGC after D2 resection.

![The C-index for OS in different nomogram models\
Nomogram A including depth of invasion, mLNS, age, location and pathological type; Nomogram B including depth of invasion, mLNR, age, location and pathological type; Nomogram C including depth of invasion, mLNS, age, location, pathological type and SIRMs. Nomogram (proposed) including depth of invasion, mLNR, age, location, pathological type and SIRMs. Abbreviation: mLNS, metastatic lymph node stage; mLNR, metastatic lymph node ratio.](oncotarget-07-37556-g004){#F4}

DISCUSSION {#s3}
==========

In the present study, we established a nomogram based on all the selected independent risk factors for RGC patients after D2 gastrectomy. Especially, inflammatory response markers were included in nomogram for the first time and showed a much more precise prediction for the prognosis of RGC.

When we constructed a nomogram that only included age at diagnosis, location, depth of invasion, mLNS, and pathological type, the C-index for OS prediction was 0.73, higher than that of the AJCC 7th staging system (0.73 vs 0.70, respectively). The result is consistent with the previous studies. For example, Han et al developed a nomogram to predict the probability of 2-year and 5-year survival in 2012 \[[@R25]\]. Hirabayashi et al also constructed and validated a nomogram for overall survival in serosa-negative, locally advanced gastric cancer \[[@R26]\]. Both of the nomograms show more accurate prognosis prediction than the TNM staging system.

Recently, mLNR has been proved to be superior to the number of positive lymph node in the accuracy of prognosis prediction \[[@R4], [@R6], [@R27], [@R28]\]. In this study, mLNR was also testified as an independent risk factor for gastric cancer. Interestingly, when mLNS was replaced by mLNR in training set, the C-index raised from 0.73 to 0.75, which was consistent with previous study \[[@R29]\]. Furthermore, when we added routine detected SIRMs into the nomogram, C-index of our nomogram raised to 0.79. Therefore, the proposed nomogram based on mLNR and other clinical pathology characteristics and SIRMs could make a much more precise prediction than other models for survival of RGC patients after D2 gastrectomy.

Indeed, the pathogenesis of tumor is closely linked to inflammatory. By promoting cell proliferation and angiogenesis, the inflammatory response can stimulate carcinogenesis \[[@R30]\]. Currently, we collect white blood cell count, neutrophil count, lymphocyte count, platelet count, total protein, albumin (ALB), globulin and C-reactive protein (CRP) in the training set. In contrast to other inflammation-related cytokines, the included SIRMs in this study is readily available and relatively cheap. All of them are evaluated in daily clinical routine worldwide \[[@R19]\].

During the past years, many studies have demonstrated the prognostic value of these routine detected SIRMs in gastric cancer patients. For example, Nozoe et al investigated 232 cases and pointed that Glasgow prognostic score (GPS), an inflammation-based prognostic score that combines CRP and ALB, can predict the prognosis of patients with operable gastric cancer. \[[@R20]\] Jung et al detected the significance of the NLR in late stage gastric cancer following resection. They suggested that the elevated preoperative NLR could predict the survival of patients and be utilized as a reliable prognostic indicator for risk stratification \[[@R21]\].

Some possible mechanisms could explain the relationship between the SIRMs and prognosis in RGC patients. First, these SIRMs like the high CRP level, could reflect progressive nutritional and functional decline of gastric cancer patients \[[@R31]\]. Second, these indexes are associated with the inherent immune system, such as macrophage function \[[@R32]\]. In addition, inflammatory response can directly promote angiogenesis and tumor metastasis \[[@R14]\].

There are several potential limitations in our study. Firstly, because of the insufficient of samples and observations, several known variables may not be included in the nomogram models. Secondly, the current nomogram was developed based on data obtained from China. Different from the Japan and Korea, most gastric cancer patients in China are often treated at advanced stage. Whether this nomogram is applicable to other regions is still uncertain.

To the best of our knowledge, this study is the first attempt to develop a prognostic nomogram which combines clinicopathology characteristics and routine detected SIRMs. Compared with previous prognostic models and the AJCC 7th staging system, the current nomogram represents the optimum prognostic discrimination and a better predictive accuracy for survival. It can be used to calculate individualized survival prediction and provide better treatment allocation after D2 gastrectomy. However, further validation whether this nomogram is applicable to all the RGC patients is required.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

From January 1, 2005 to December 31, 2010, among gastric cancer patients after D2 gastrectomy at the Department of Gastric and Pancreatic Surgery at the Sun Yat-sen University Cancer Center, we collected the data of RGC patients who met the following inclusion criteria: no history of receiving anti-cancer therapy before surgery; no history of chronic infectious diseases (e.g. hepatitis, tuberculosis) or inflammatory diseases; no history of liver and kidney dysfunctions; no history of other malignancies; complete resection of cancer with D2 lymphadenectomy. Ethical approval was obtained before surgery.

The data of patients\' clinicpathological characteristics (location, size, histology, depth of invasion, mLNS, mLNR) and the routine pretreatment blood SIRMs (white blood cell count, neutrophil count, lymphocyte count, platelet count, total protein, ALB, globulin, CRP were collected. The tumor location was categorized as upper, middle and lower by the center of the lesion. Histology was categorized by differentiated type (papillary adenocarcinoma, well-differentiated tubular adenocarcinoma, and moderately differentiated tubular adenocarcinoma) and undifferentiated type (poorly differentiated tubular adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma) \[[@R25]\]. The depth of invasion was categorized by mucosa or submucosa, proper muscle, subs-serosa, serosa and adjacent invasion. The pathological tumor stage (IA, IB, IIA, IIB, IIIA, IIIB or IIIC) and mLNS (0, 1\~2, 3\~6, 7\~15 or \>16) were categorized according to the AJCC 7th TNM staging system. \[[@R3]\] The mLNR was calculated as the number of positive lymph nodes divided by the number of examined lymph nodes. NLR was defined as neutrophil count divided by lymphocyte count. The CAR was defined as CRP divided by ALB. Follow-up duration was measured as the time from the date of surgery to the last follow-up. OS was defined as the time form surgery to death due to any cause or the last follow-up. The survival status was recorded according to the latest follow-up.

Follow up {#s4_2}
---------

Postoperative follow-up included clinical and laboratory examinations every 3 months for the first 2 years, every 6 months from the 3rd to 5th year, annually after the gastrectomy or until the patient died.

Statistics analysis {#s4_3}
-------------------

Based on clinical findings, categorical variables were grouped before modeling. The best cutoff points for continuous variables were performed by X-tile (<http://www.tissuearray.org/rimmlab/>). The continuous variables were divided into three groups. Associations between each group can be calculated by various standard statistical tests, including the log-rank test for survival and means tests for associations between other marker data. The X-tile can provide the optimal division of the data by P values obtained from a lookup table \[[@R33]\].

Independent risk factors were identified by the forward method. OS estimation and survival curves were performed by the Kaplan-Meier method and valided by the log-rank test.

Nomogram was established based on the training set data, and Cox PH regression was used for screening independent risk factors. On the basis of all the independent prognostic factors, a nomogram was constructed by using the package of *rms* in R software version 3.1.3 (<http://www.r-project.org/>) for predicting 1-year, 3-year, 5-year overall survival. We used the method of bootstraps with 1000 resample for these activities. Harrell\'s C-index was used in the nomogram for evaluating the discrimination \[[@R34]\]. It can estimate the probability of concordance between the observed and predicted OS. The higher the C-index, the more precise was the survival prediction.

The validation was carried out by using the validation set. Discrimination between the proposed nomogram and AJCC 7th staging system was performed with the *roccp.cens* package in R soft. According to the nomogram-predicted probabilities, calibration were carried out by grouping all the training set patients, validation set and primary cohort, then the mean of the groups were compared with observed Kaplan-Meier OS estimation. P value \<0.05 was considered to be statistically significant. All analyses were performed by the software statistical package for social sciences version 19.0 (SPSS, Chicago, IL) and the R software version 3.13 (<http://www.r-project.org/>).

SUPPLEMENTARY FIGURES {#s5}
=====================
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